+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Treatment of acute myeloid leukemia in patients upper the age of 60 years Report of the AML97-038 study of the East German hematology and oncology study group



Treatment of acute myeloid leukemia in patients upper the age of 60 years Report of the AML97-038 study of the East German hematology and oncology study group



Onkologie 23(Sonderheft 7): 29




Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 035980796

Download citation: RISBibTeXText


Related references

Treatment of Acute Myeloid Leukemia in Patients Upper the Age of 60 Years Report of the AML97-38 Study of the East German Hematology and Oncology Study Group. Blood 100(11): Abstract No 1337, 2002

High CR-rate after intensive chemotherapy but disappointing results after palliative treatment in patients with acute myelloid leukemia above the age of 60 years: An analysis of the AML97#38 study of the east German hematology and oncollogy study group (OSHO). 2007

Long-term follow-up of the AML97 study for patients aged 60 years and above with acute myeloid leukaemia: a study of the East German Haematology and Oncology Study Group (OSHO). Journal of Cancer Research and Clinical Oncology 142(1): 305-315, 2016

Treatment of acute myelogenous leukemia with intermediate-dose cytarabine for both induction and postremission therapy An east German hematology and oncology study group protocol. Annals of Hematology 77(Suppl. 2): S175, 1998

Use of recombinant GM-CSF during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukemia: final report of AML-11, a phase III randomized study of the Leukemia Cooperative Group of European Organisation for the Research and Treatment of Cancer and the Dutch Belgian Hemato-Oncology Cooperative Group. Blood 90(8): 2952-2961, 1997

Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL). Annals of Oncology 26(7): 1434-1440, 2015

ASXL1 mutations in younger adult patients with acute myeloid leukemia: a study by the German-Austrian Acute Myeloid Leukemia Study Group. Haematologica 100(3): 324-330, 2015

Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60 years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. Journal of Clinical Oncology 20(15): 3254-3261, 2002

Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent AML Interim results of a prospective randomized intergroup study of the east German study group hematology/oncology and the SHG-AML-96 study group. Blood 102(11): 615a, 2003

Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO). Journal of Cancer Research and Clinical Oncology 132(4): 205-212, 2006

Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study. Journal of Clinical Oncology 25(15): 1986-1992, 2007

Standard operating procedures and organization of German Phase I, II, and III Study Groups, New Drug Development Group , and Study Group of Pharmacology in Oncology and Hematology of the Association for Medical Oncology of the German Cancer Society. Onkologie 21(Suppl. 3): I-VI, 1-70, 1998

Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group. Journal of Clinical Oncology 29(19): 2709-2716, 2011

Treatment of acute myelogenous leukemia in patients over 50 years of age with V-TAD: A Southwest Oncology Group study. American Journal of Hematology 48(4): 228-232, 1995

BOP Versus COP in Advanced Indolent Lymphomas - Results of a Randomized Multicenter Phase III Study of the East German Study Group Hematology/Oncology. Blood 100(11): Abstract No 3082, 2002